Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Medicure Inc. (MCUJF : OTC)

• Company Description    Medicure Inc is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine. In addition to MC-4232, they are also conducting Phase II clinical trials with MC-1, which is focused on the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke. Number of Employees: 22

• Price / Volume Information    Yesterday's Closing Price: $0.80 Daily Weekly Monthly 20 Day Moving Average: 262 shares Shares Outstanding: 10.44 (millions) Market Capitalization: $8.39 (millions) Beta: 0.97 52 Week High: $0.97 52 Week Low: $0.71 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.55% -20.62% 12 Week -2.09% -9.49% Year To Date 0.53% -7.58%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 - 1250 Waverley Street - Winnipeg,A2 R3T 6C6 CAN ph: 204-487-7412 fax: 204-488-9823 ir@medicure.com http://www.medicure.com

• General Corporate Information    Officers Albert D. Friesen - Chairman and Chief Executive Officer Neil Owens - President and Chief Operating Officer Haaris Uddin - Chief Financial Officer Reuben Saba - Vice-President Arnold Naimark - Director Peer Information Medicure Inc. (GSAC) Medicure Inc. (CASIF) Medicure Inc. (ALCD.) Medicure Inc. (OMNN) Medicure Inc. (CGPI.) Medicure Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 58469E408 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/19/26 Share - Related Items Shares Outstanding: 10.44 Most Recent Split Date: 11.00 (0.07:1) Beta: 0.97 Market Capitalization: $8.39 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/19/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.91 Price/Cash Flow: - Price / Sales: 0.37 EPS Growth vs. Year Ago Period: 40.00% vs. Previous Quarter: 89.66% Sales Growth vs. Year Ago Period: 51.65% vs. Previous Quarter: -5.47% ROE 03/31/26 - -42.01 12/31/25 - -41.55 09/30/25 - -17.91 ROA 03/31/26 - -25.47 12/31/25 - -25.94 09/30/25 - -11.95 Current Ratio 03/31/26 - - 12/31/25 - 1.02 09/30/25 - 1.44 Quick Ratio 03/31/26 - - 12/31/25 - 0.77 09/30/25 - 1.00 Operating Margin 03/31/26 - -21.65 12/31/25 - -24.61 09/30/25 - -13.10 Net Margin 03/31/26 - -21.65 12/31/25 - -24.61 09/30/25 - -13.10 Pre-Tax Margin 03/31/26 - - 12/31/25 - -23.87 09/30/25 - -12.08 Book Value 03/31/26 - - 12/31/25 - 0.89 09/30/25 - 1.20 Inventory Turnover 03/31/26 - - 12/31/25 - 4.64 09/30/25 - 3.63 Debt-to-Equity 03/31/26 - - 12/31/25 - 0.03 09/30/25 - 0.03 Debt-to-Capital 03/31/26 - - 12/31/25 - 3.21 09/30/25 - 2.91

Powered by Zacks Investment Research ©